Accuray Incorporated

NasdaqGS:ARAY Stock Report

Market Cap: US$276.6m

Accuray Past Earnings Performance

Past criteria checks 0/6

Accuray's earnings have been declining at an average annual rate of -44.4%, while the Medical Equipment industry saw earnings growing at 12.5% annually. Revenues have been growing at an average rate of 3.3% per year.

Key information

-44.4%

Earnings growth rate

-43.6%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate3.3%
Return on equity-9.1%
Net Margin-1.0%
Last Earnings Update31 Dec 2024

Recent past performance updates

Recent updates

Accuray Incorporated (NASDAQ:ARAY) Shares Fly 25% But Investors Aren't Buying For Growth

Jan 18
Accuray Incorporated (NASDAQ:ARAY) Shares Fly 25% But Investors Aren't Buying For Growth

Accuray - There's Value If Linac Sales Accelerate, But That's A Big 'If'

Jan 07

Health Check: How Prudently Does Accuray (NASDAQ:ARAY) Use Debt?

Dec 19
Health Check: How Prudently Does Accuray (NASDAQ:ARAY) Use Debt?

Accuray Incorporated: Cheap, But With Caveats

Dec 05

Accuray Remains A Perpetual 'Next Year Is Our Year' Story

Aug 18

Accuray Incorporated's (NASDAQ:ARAY) 28% Dip In Price Shows Sentiment Is Matching Revenues

Aug 13
Accuray Incorporated's (NASDAQ:ARAY) 28% Dip In Price Shows Sentiment Is Matching Revenues

Lacklustre Performance Is Driving Accuray Incorporated's (NASDAQ:ARAY) 25% Price Drop

May 21
Lacklustre Performance Is Driving Accuray Incorporated's (NASDAQ:ARAY) 25% Price Drop

Analysts Have Lowered Expectations For Accuray Incorporated (NASDAQ:ARAY) After Its Latest Results

May 04
Analysts Have Lowered Expectations For Accuray Incorporated (NASDAQ:ARAY) After Its Latest Results

Are Investors Undervaluing Accuray Incorporated (NASDAQ:ARAY) By 25%?

May 03
Are Investors Undervaluing Accuray Incorporated (NASDAQ:ARAY) By 25%?

Accuray Getting Very Little Love Ahead Of A Coming Revenue Ramp

Apr 07

Is Accuray (NASDAQ:ARAY) A Risky Investment?

Feb 03
Is Accuray (NASDAQ:ARAY) A Risky Investment?

Why Investors Shouldn't Be Surprised By Accuray Incorporated's (NASDAQ:ARAY) 26% Share Price Plunge

Aug 17
Why Investors Shouldn't Be Surprised By Accuray Incorporated's (NASDAQ:ARAY) 26% Share Price Plunge

These 4 Measures Indicate That Accuray (NASDAQ:ARAY) Is Using Debt Extensively

Apr 13
These 4 Measures Indicate That Accuray (NASDAQ:ARAY) Is Using Debt Extensively

The Return Trends At Accuray (NASDAQ:ARAY) Look Promising

Mar 14
The Return Trends At Accuray (NASDAQ:ARAY) Look Promising

Accuray (NASDAQ:ARAY) Takes On Some Risk With Its Use Of Debt

Dec 01
Accuray (NASDAQ:ARAY) Takes On Some Risk With Its Use Of Debt

Accuray (NASDAQ:ARAY) Is Doing The Right Things To Multiply Its Share Price

Oct 27
Accuray (NASDAQ:ARAY) Is Doing The Right Things To Multiply Its Share Price

Accuray launches CyberKnife platform in Africa for cancer patients

Sep 30

Accuray GAAP EPS of -$0.04 beats by $0.03, revenue of $110.02M beats by $4.7M

Aug 10

Here's Why Accuray (NASDAQ:ARAY) Has A Meaningful Debt Burden

Jul 08
Here's Why Accuray (NASDAQ:ARAY) Has A Meaningful Debt Burden

Accuray (NASDAQ:ARAY) Might Have The Makings Of A Multi-Bagger

Jun 15
Accuray (NASDAQ:ARAY) Might Have The Makings Of A Multi-Bagger

Revenue & Expenses Breakdown

How Accuray makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:ARAY Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 24453-49244
30 Sep 24444-179346
30 Jun 24447-169248
31 Mar 24431-219153
31 Dec 23447-159158
30 Sep 23455-79257
30 Jun 23448-99257
31 Mar 23439-109758
31 Dec 22417-129657
30 Sep 22419-109457
30 Jun 22430-59458
31 Mar 22431-139259
31 Dec 21437-129358
30 Sep 21418-88955
30 Jun 21396-68553
31 Mar 2138058350
31 Dec 2037788147
30 Sep 20379148149
30 Jun 2038348750
31 Mar 2040539254
31 Dec 19409-19755
30 Sep 19413-1710156
30 Jun 19419-1610656
31 Mar 19415-1610955
31 Dec 18412-2411056
30 Sep 18410-2411157
30 Jun 18405-2410857
31 Mar 18403-2810556
31 Dec 17401-2410355
30 Sep 17388-2910252
30 Jun 17383-3010150
31 Mar 17366-3210051
31 Dec 16374-2610252
30 Sep 16396-2210655
30 Jun 16399-2610757
31 Mar 16406-2410857
31 Dec 15398-2810657
30 Sep 15387-3210755
30 Jun 15380-4010956
31 Mar 15380-4411154
31 Dec 14380-4611355
30 Sep 14375-4211055
30 Jun 14369-3510754
31 Mar 14352-4410355

Quality Earnings: ARAY is currently unprofitable.

Growing Profit Margin: ARAY is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ARAY is unprofitable, and losses have increased over the past 5 years at a rate of 44.4% per year.

Accelerating Growth: Unable to compare ARAY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ARAY is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (18%).


Return on Equity

High ROE: ARAY has a negative Return on Equity (-9.13%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 07:07
End of Day Share Price 2025/02/07 00:00
Earnings2024/12/31
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Accuray Incorporated is covered by 22 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason WittesBrean Capital
Neil ChatterjiB. Riley Securities, Inc.
Marie ThibaultBTIG